公司库 > 公司详情页

$ 3.86

+0.20(5.46%)

04-24 16:08

Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
最高：3.92今开：3.65成交量：62.20万股换手：1.45%
最低：3.62昨收：3.66成交额：235.72万振幅：8.33%
52周最高：8.28量比：1.40市盈率(TTM)：亏损市净率：4.44
52周最低：3.46委比：-90.48%市盈率(静)：亏损市销率：82.93
每股收益：-1.57股息：--每手股数：1总市值：1.65亿
每股净资产：0.87股息率：--最小价差：0.01总股本：4283.66万
机构持股：--Beta：1.86空头回补天数：14.47货币单位：USD
最新获投

债权融资 $3750万

2019-02-25
最新动态
暂无数据
五力模型
财务指标
单位:美元
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
流动资产
5,847.20万
6,447.60万
4,323.10万
5,245.30万
6,832.80万
现金及短期投资
5,683.40万
6,291.10万
4,153.80万
5,116.50万
6,604.90万
短期应收账款
28.50万
17.00万
22.60万
27.80万
21.10万
存货
13.10万
13.90万
12.20万
12.70万
9.00万
其他流动资产
122.20万
125.60万
134.50万
88.30万
197.80万
非流动资产
1,198.70万
1,220.90万
1,220.00万
1,194.60万
1,134.70万
厂房及设备净资产
1,037.30万
1,059.50万
1,047.80万
1,021.80万
961.90万
项目总投资及垫款
161.40万
161.40万
161.40万
172.80万
172.80万
长期应收票据
--
--
--
--
--
无形资产
--
--
--
--
--
递延所得税资产
--
--
--
--
--
其他资产
--
--
10.80万
--
--
合计总资产
7,045.90万
7,668.50万
5,543.10万
6,439.90万
7,967.50万
流动负债
1,189.90万
1,315.10万
1,342.60万
1,094.50万
1,313.00万
短期债务（含部分LTD）
608.20万
607.10万
554.50万
399.30万
244.40万
应付账款
213.70万
347.70万
357.10万
259.90万
630.70万
应付所得税
--
--
--
--
--
其他流动负债
368.00万
360.30万
431.00万
435.30万
437.90万
非流动负债
1,283.10万
1,435.00万
1,585.80万
1,753.20万
1,852.00万
长期负债
954.80万
1,101.40万
1,247.10万
1,392.40万
1,537.40万
拨备风险及费用
--
--
--
--
--
递延所得税负债
--
--
--
--
--
其他负债
328.30万
333.60万
338.70万
360.80万
314.60万
合计总负债
2,473.00万
2,750.10万
2,928.40万
2,847.70万
3,165.00万
股东权益合计
4,572.90万
4,918.40万
2,614.70万
3,592.20万
4,802.50万
非股权储备
--
--
--
--
--
优先股-账面价值
0.00
0.00
0.00
0.00
0.00
普通股权益（合计）
4,572.90万
4,918.40万
2,614.70万
3,592.20万
4,802.50万
累计少数股东权益
--
--
--
--
--
权益总额
4,572.90万
4,918.40万
2,614.70万
3,592.20万
4,802.50万
负债与股东权益合计
7,045.90万
7,668.50万
5,543.10万
6,439.90万
7,967.50万
每股账面价值
1.19
1.32
0.88
1.22
1.65
每股账面价值-有形
1.19
1.32
0.88
1.22
1.65
单位:美元
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
营业总收入
64.80万
34.00万
48.70万
52.30万
43.80万
-营业成本
71.90万
64.50万
64.10万
60.70万
45.80万
毛利
-7.10万
-30.50万
-15.40万
-8.40万
-2.00万
-销售管理及行政费用
1,349.30万
1,315.00万
1,214.50万
1,302.30万
1,831.90万
-其他运营费用
--
--
--
--
--
计息税前利润
-1,356.40万
-1,345.50万
-1,229.90万
-1,310.70万
-1,833.90万
+非经营收入(支出)
21.50万
17.60万
10.40万
12.00万
11.30万
-非经常性支出
--
--
41.70万
208.90万
--
-利息支出
45.50万
48.60万
49.00万
49.10万
46.80万
税前净利润
-1,380.40万
-1,376.50万
-1,310.20万
-1,556.70万
-1,869.40万
-所得税
--
--
--
--
--
+其他税后调整
0.00
0.00
0.00
0.00
0.00
+联署公司盈利权益
--
--
--
--
--
合并净利润
-1,380.40万
-1,376.50万
-1,310.20万
-1,556.70万
-1,869.40万
-少数股东权益开支
--
--
--
--
--
净利润
-1,380.40万
-1,376.50万
-1,310.20万
-1,556.70万
-1,869.40万
-优先股股息
--
--
--
--
--
一般可用收入净利润
-1,380.40万
-1,376.50万
-1,310.20万
-1,556.70万
-1,869.40万
每股基本收益
-0.37
-0.40
-0.44
-0.54
-0.64
摊薄每股收益
-0.37
-0.40
-0.44
-0.54
-0.64
息税折旧摊销前利润
-1,299.80万
-1,289.00万
-1,177.10万
-1,262.50万
-1,798.50万
单位:美元
2017-12-31
2016-12-31
2015-12-31
2013-12-31
净收益
-6,338.60万
-4,470.30万
-3,974.80万
-1,334.40万
+折旧损耗及摊稍
162.50万
88.10万
75.40万
40.40万
+递延税及投资税减免
--
--
--
--
+其他经营基金
773.80万
774.50万
474.80万
53.50万
营运资金
-5,402.30万
-3,607.70万
-3,424.60万
-1,240.50万
+特别项目
--
--
--
--
+营运资金变动
355.00万
207.60万
50.30万
-24.00万
经营现金流
-5,047.30万
-3,400.10万
-3,374.30万
-1,264.50万
资本支出
-825.20万
-191.90万
-177.80万
-38.70万
收购所得净资产
--
--
--
--
固定资产和业务出售收入
5,000.00
2,000.00
7,000.00
--
投资买卖净额
3,531.40万
3,748.50万
-3,679.80万
--
非现金项目
0.00
0.00
0.00
0.00
投资现金流
2,706.70万
3,556.80万
-3,856.90万
-38.70万
发放现金股利
--
--
--
--
股本变动
3,019.90万
110.40万
6,606.80万
7,000.00
发行/削减债务净额
240.00万
--
39.70万
667.60万
其他融资基金
-59.10万
-51.90万
-76.20万
--
筹资现金流
3,200.80万
58.50万
6,570.30万
668.30万
汇率影响
--
--
--
--
杂项基金
--
--
--
--
现金净流动
860.20万
215.20万
-660.90万
-634.90万
自由现金流
-5,872.50万
-3,592.00万
-3,552.10万
-1,303.20万
公司高管
Daniel M. Bollag
Daniel M. Bollag holds the position of Senior Vice President-Regulatory Affairs & Quality at Ocular Therapeutix, Inc. In his past career he held the position of Director-Project Planning & Management at Bristol-Myers Squibb Co., Director-US Regulatory Liaison at Sanofi-Aventis Pharmaceuticals, Senior Vice President-Regulatory Affairs & Quality at ARIAD Pharmaceuticals, Inc., Senior Project Manager at Merck Research Laboratories and Vice President-Regulatory Affairs at Genzyme Corp. He received an undergraduate degree from The Pennsylvania State University and a doctorate from Cornell University.
Pauline Jen Ryan
Pauline Jen Ryan is Partner at Red Sky Partners LLC and Head-Business & Corporate Development at Ocular Therapeutix, Inc. In the past she was Chief Executive Officer at Verik Bio, Inc., Senior Vice President-Business Operations at Proteostasis Therapeutics, Inc. and SVP-Corporate Development & Operations at ImmunoGen, Inc. Ms. Ryan received an undergraduate degree from Northwestern University and an MBA from Kellogg School of Management.
William James O'Shea
Currently, William James O'Shea occupies the position of Chairman for Correvio Pharma Corp. He is also on the board of Ocular Therapeutix, Inc., BTG Plc and Zalicus Pharmaceuticals Ltd. In his past career he was Senior VP-Sales, Marketing & Medical Affairs at Zeneca Pharmaceuticals, Vice Chairman for Sunovion Pharmaceuticals, Inc. and Chairman of National Pharmaceutical Council. He received an undergraduate degree from The University of Liverpool.
Bruce A. Peacock
Bruce A. Peacock is a businessperson who has been at the helm of 5 different companies and currently is Venture Partner at SV Health Investors LLC. He is also on the board of 8 other companies. In the past he was Treasurer, Chief Financial & Business Officer at Ophthotech Corp., Chairman at Alba Therapeutics Corp., President, Chief Executive Officer & Director at Adolor Corp., President, Chief Executive Officer & Director at Orthovita, Inc., Chief Executive Officer & Director at The Little Clinic LLC, Chief Operating Officer & Director at Cephalon, Inc. and Chief Financial Officer & Senior Vice President at Centocor, Inc. Bruce A. Peacock received an undergraduate degree from Villanova University.
Richard L. Lindstrom
Founder of Minnesota Eye Consultants PA and Phillips Eye Institute, Richard L. Lindstrom is a businessperson who has been the head of 8 different companies and presently is Chairman at Vision Foundation, Inc., Chairman, President & Chief Executive Officer of Lindstrom Restoration, Medical Director of Sightpath Medical, Inc., Partner at Flying L Management LLC, Chief Executive Officer of Minnesota Eye Consultants PA and Medical Director at Midwest Surgical Services, Inc. Dr. Lindstrom is also Chairman at American Society of Cataract & Refractive Surgery Foundation and Associate Director at Minnesota Lions Vision Foundation, Inc. and on the board of 19 other companies. Dr. Lindstrom previously held the position of President at International Refractive Surgery Club, Director & Chief Medical Officer at TLC Vision Corp., President at International Society of Refractive Surgery, Director at Refractec, Inc., Director at The American Society of Cataract & Refractive Surgery, President of International Intra-Ocular Implant Club and Professor at the University of Minnesota. Dr. Lindstrom received a doctorate and an undergraduate degree from The College of Liberal Arts at the University of Minnesota.
Daniel M. Bollag
Daniel M. Bollag holds the position of Senior Vice President-Regulatory Affairs & Quality at Ocular Therapeutix, Inc. In his past career he held the position of Director-Project Planning & Management at Bristol-Myers Squibb Co., Director-US Regulatory Liaison at Sanofi-Aventis Pharmaceuticals, Senior Vice President-Regulatory Affairs & Quality at ARIAD Pharmaceuticals, Inc., Senior Project Manager at Merck Research Laboratories and Vice President-Regulatory Affairs at Genzyme Corp. He received an undergraduate degree from The Pennsylvania State University and a doctorate from Cornell University.
Pauline Jen Ryan
Pauline Jen Ryan is Partner at Red Sky Partners LLC and Head-Business & Corporate Development at Ocular Therapeutix, Inc. In the past she was Chief Executive Officer at Verik Bio, Inc., Senior Vice President-Business Operations at Proteostasis Therapeutics, Inc. and SVP-Corporate Development & Operations at ImmunoGen, Inc. Ms. Ryan received an undergraduate degree from Northwestern University and an MBA from Kellogg School of Management.
William James O'Shea
Currently, William James O'Shea occupies the position of Chairman for Correvio Pharma Corp. He is also on the board of Ocular Therapeutix, Inc., BTG Plc and Zalicus Pharmaceuticals Ltd. In his past career he was Senior VP-Sales, Marketing & Medical Affairs at Zeneca Pharmaceuticals, Vice Chairman for Sunovion Pharmaceuticals, Inc. and Chairman of National Pharmaceutical Council. He received an undergraduate degree from The University of Liverpool.
Bruce A. Peacock
Bruce A. Peacock is a businessperson who has been at the helm of 5 different companies and currently is Venture Partner at SV Health Investors LLC. He is also on the board of 8 other companies. In the past he was Treasurer, Chief Financial & Business Officer at Ophthotech Corp., Chairman at Alba Therapeutics Corp., President, Chief Executive Officer & Director at Adolor Corp., President, Chief Executive Officer & Director at Orthovita, Inc., Chief Executive Officer & Director at The Little Clinic LLC, Chief Operating Officer & Director at Cephalon, Inc. and Chief Financial Officer & Senior Vice President at Centocor, Inc. Bruce A. Peacock received an undergraduate degree from Villanova University.
Richard L. Lindstrom
Founder of Minnesota Eye Consultants PA and Phillips Eye Institute, Richard L. Lindstrom is a businessperson who has been the head of 8 different companies and presently is Chairman at Vision Foundation, Inc., Chairman, President & Chief Executive Officer of Lindstrom Restoration, Medical Director of Sightpath Medical, Inc., Partner at Flying L Management LLC, Chief Executive Officer of Minnesota Eye Consultants PA and Medical Director at Midwest Surgical Services, Inc. Dr. Lindstrom is also Chairman at American Society of Cataract & Refractive Surgery Foundation and Associate Director at Minnesota Lions Vision Foundation, Inc. and on the board of 19 other companies. Dr. Lindstrom previously held the position of President at International Refractive Surgery Club, Director & Chief Medical Officer at TLC Vision Corp., President at International Society of Refractive Surgery, Director at Refractec, Inc., Director at The American Society of Cataract & Refractive Surgery, President of International Intra-Ocular Implant Club and Professor at the University of Minnesota. Dr. Lindstrom received a doctorate and an undergraduate degree from The College of Liberal Arts at the University of Minnesota.
高管交易状态
交易日期 交易人 职位 类型 交易份额 价格
2016-12-14
Sawhney (Amarpreet)
Chief Executive Officer
Buy
45300
7.85
2016-08-04
Sawhney (Amarpreet)
Chief Executive Officer
Buy
58357
1.35
2016-06-08
Sawhney (Amarpreet)
Chief Executive Officer
Buy
10000
6.70
2015-11-16
Sawhney (Amarpreet)
Chief Executive Officer
Buy
10000
8.25
2015-09-14
Fortune (James)
Chief Operating Officer
Sell
9470
17.16
2015-09-13
Sawhney (Amarpreet)
Chief Executive Officer
Buy
11328
16.36
2015-09-13
Sawhney (Amarpreet)
Chief Executive Officer
Buy
3672
16.92
查看更多
持股状况
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Royal Bank Of Canada
85573
0.22%
3699
4.52%
2018-06-30
Opaleye Management Inc
1111000
2.89%
1111000
--
2018-06-30
BlackRock Inc
1284722
3.34%
229127
21.71%
2018-06-30
Vanguard Group Inc
1335198
3.47%
-9343
-0.69%
2018-06-30
Wellington Management Company LLP
1513007
3.93%
63142
4.36%
2018-06-30
Summer Road LLC
3027488
8.15%
3027488
--
2018-01-29
Versant Venture Management LLC
2215384
5.76%
--
--
2018-06-30
Jennison Associates LLC
2319255
6.03%
26503
1.16%
2018-06-30
Fidelity Management and Research Company
3239448
8.42%
--
--
2018-06-30
SVLSF IV LLC
1605207
5.41%
--
--
2017-12-31
BlackRock Institutional Trust Company NA
681160
1.77%
40143
6.26%
2018-06-30
Deltec Asset Management LLC
532986
1.39%
-53253
-9.08%
2018-06-30
Bridgeway Capital Management, Inc
103300
0.27%
--
--
2018-06-30
Endurant Capital Management LP
142775
0.37%
-35686
-20.00%
2018-06-30
D. E. Shaw & Co LP
174023
0.45%
174023
--
2018-06-30
Elias Asset Management Inc
191766
0.50%
44820
30.50%
2018-06-30
Morgan Stanley Smith Barney LLC
208711
0.54%
-63
-0.03%
2018-06-30
Geode Capital Management, LLC
289194
0.75%
54649
23.30%
2018-06-30
Northern Trust Investments N A
362627
0.94%
38101
11.74%
2018-06-30
State Street Corp
432980
1.13%
59057
15.79%
2018-06-30
K2/D&S Management Co LLC
84555
0.23%
--
--
2018-05-31
BNY Mellon Investment Management
83578
0.22%
13448
19.18%
2018-06-30
Northern Trust Asset Management
78190
0.21%
9325
13.54%
2018-06-30
Credit Suisse AG
120000
0.41%
--
--
2017-11-30
Prudential Investment Management Inc
1995968
6.73%
8602
0.43%
2017-12-31
Columbus Circle Investors
171024
0.59%
171024
--
2017-03-31
SV Life Sciences Advisers, LLC
1605207
5.46%
--
--
2017-09-30
J. P. Morgan Chase Bank NA
150600
0.53%
--
--
2017-09-30
J.P. Morgan Investment Management Inc
182100
0.64%
-5800
-3.09%
2017-09-30
Credit Suisse First Boston (CSFB)
245144
0.83%
229349
1452.04%
2017-09-30
Bailard Inc
146752
0.50%
--
--
2017-09-30
BlackRock Fund Advisors
731969
2.71%
-877
-0.12%
2017-12-28
Deutsche Asset Mgmt Invst Gesenschaft
102778
0.35%
2082
2.07%
2017-06-30
Versant Ventures III, LLC
2215384
8.95%
-747000
-25.22%
2015-12-31
Polaris Venture Management Co. V,LLC
998713
4.01%
--
--
2016-09-30
First Republic Inv Mgmt Inc
336320
1.35%
80275
31.35%
2016-09-30
Federated Global Inv Mgmt Corp
261700
1.05%
-1134587
-81.26%
2016-09-30
Deutsche Asset & Wealth Management Investment GmbH
100766
0.40%
-159
-0.16%
2017-02-08
Farhad Khosravi
1112422
3.00%
46705038
--
1999-11-30
Wellington Management Group
1296690
3.00%
54441530
0.10%
1999-11-30
Entities affiliated with Polaris Ventures
2030009
3.00%
85229928
0.10%
1999-11-30
CHV II L.P.
2100138
3.00%
88174294
0.10%
1999-11-30
James Garvey
2589710
3.00%
108728974
0.10%
1999-11-30
Amarpreet Sawhney, Ph.D.
2868530
3.00%
120435232
0.10%
1999-11-30
Charles Warden
2966487
3.00%
124547957
0.10%
1999-11-30
持有者 持有份额 持股比例 份额变化 变化率 报告日期
AXA 2000 Managed Volatility K
48916
0.13%
--
--
2018-07-31
Prudential Jennison Health Sciences A
1431743
3.72%
--
--
2018-07-31
Vanguard Total Stock Mkt Idx
747776
1.94%
30500
4.25%
2018-07-31
Vanguard Extended Market Idx Inv
412805
1.07%
--
--
2018-07-31
Fidelity Advisor
410721
1.07%
-252328
-38.06%
2018-07-31
iShares Russell 2000 Growth
317014
0.80%
-306
-0.10%
2018-09-12
Fidelity
182000
0.47%
--
--
2018-07-31
State Street Russell Small/Mid Cap Idx Fd Cl I
84711
0.29%
2105
2.55%
2017-06-30
Bridgeway Ultra-Small Company Market
100000
0.26%
--
--
2018-06-30
JHancock Seaport A
113760
0.30%
--
--
2018-07-31
BlackRock Extended Equity Market K
41774
0.11%
1136
2.80%
2018-06-30
Fidelity Spartan
54730
0.14%
--
--
2018-07-31
BlackRock Russell 2000
45578
0.12%
11513
33.80%
2018-06-30
The Vanguard Russell 2000 Growth Index
57115
0.15%
--
--
2018-07-31
Schwab Small Cap Index
63770
0.17%
--
--
2018-07-31
Northern Trust Russell 2000 Index Fund - DC - Non-Lending
77775
0.20%
-415
-0.53%
2018-07-31
iShares Micro-Cap
85635
0.22%
--
--
2018-09-12
CREF Stock R1
48828
0.13%
1918
4.09%
2018-06-30
Vanguard Instl Ttl Stk Mkt Idx InstlPls
47842
0.12%
--
--
2018-06-30
Franklin K2 Alternative Strategies A
41503
0.11%
--
--
2018-05-31
Vanguard Health Care ETF
68369
0.18%
-264
-0.38%
2018-04-30
JPMorgan Insurance Tr Small Cap Core 1
33400
0.11%
-900
-2.62%
2017-09-30
VY JPMorgan Small Cap Core Equity S
71900
0.24%
-2200
-2.97%
2017-09-30
JPMorgan Small Cap Core Select
43100
0.15%
1200
2.86%
2017-11-30
BlackRock Russell 2500
31447
0.11%
5681
22.05%
2017-09-30
CREF Equity Index R1
33966
0.14%
24450
256.94%
2016-12-31
Federated Kaufmann Small Cap A
261700
1.05%
93300
55.40%
2016-09-30
American Funds NVIT Global Growth
795000
3.20%
--
--
2015-09-30
American Funds IS® Gbl Sm Cap
887780
3.60%
--
--
2015-09-30
Fidelity® Select Biotechnology Portfolio
936128
3.80%
--
--
2015-09-30
Fidelity® Independence Fund
957100
3.90%
--
--
2015-09-30
Federated Kaufmann Fund
1400000
5.70%
317400
29.30%
2015-09-30
Prudential Jennison Health Sciences
518799
2.10%
--
--
2015-09-30
Federated Kaufmann Small Cap Fund
284830
1.10%
32030
12.70%
2015-09-30
iShares Russell 2000 (AU)
236934
0.90%
-150
-0.10%
2015-11-18
Fidelity® Trend Fund
207828
0.80%
-130525
-38.60%
2015-09-30
Fidelity Advisor® Biotechnology Fund
196271
0.80%
--
--
2015-09-30
Hartford Healthcare Fund
185602
0.80%
4710
2.60%
2015-09-30
Fidelity® Select Pharmaceuticals Port
145900
0.60%
145900
--
2015-09-30
Fidelity® Small Cap Growth Fund
132500
0.50%
132500
--
2015-07-31
VA CollegeAmerica Small Cap World
1955700
7.90%
--
--
2015-09-30